matricelf.comCrawled Nov 15, 2026
Regenerating the Future of Medicine - Personalized platform for autologous regenerative medicine
Matricelf has obtained feedback from the U.S. Food and Drug Administration (FDA) concerning its spinal cord injury treatment program. The company is now reviewing the regulatory input to advance its development efforts. The feedback pertains to a potential therapeutic approach for spinal cord injury patients.
Matricelf completes a GLP safety study for its personalized regenerative medicine platform, clearing a key milestone for transitioning from preclinical development to clinical trials. The study supports the company’s progress toward initiating its first-in-human trial for spinal cord injury treatments. Regulatory approval pathways now move forward with validated safety data.
Tel Aviv University is leading the world’s first human spinal cord implant surgery using a patient’s own cells. The procedure, set to occur in Israel, aims to restore mobility for paralyzed patients through regenerative medicine techniques. This breakthrough could enable patients to stand and walk again.
Tel Aviv University researchers transplant lab-grown human spinal cord stem cells in a clinical trial. The procedure targets paralyzed patients, following successful animal testing. Israel’s Health Ministry approved the human trials, marking a global first in regenerative medicine.
Tel Aviv University researchers implant an artificial human spinal cord in mice, enabling over 80% of chronically paralyzed test subjects to regain movement. The breakthrough involves a bioengineered solution targeting spinal cord injuries. Early tests show restored mobility without specifying long-term effects or human applications.
Israeli scientists create the first 3D human spinal cord tissue implants, offering potential mobility restoration for individuals with long-term paralysis. The breakthrough, published in *Advanced Science*, marks a key advance in regenerative medicine research. Early tests suggest the engineered tissue may help reconnect damaged spinal pathways.

Matricelf builds autologous 3D tissue engineering platform for regenerative medicine targeting patients with severe neurological injuries.